MetaCap

Actinium Pharmaceuticals (Delaware) (ATNM) vs Stablecoin Development (SDEV)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Actinium Pharmaceuticals (Delaware) (ATNM) has outperformed Stablecoin Development (SDEV) over the past year, losing 21.1% versus a loss of 88.4%. Over five years, ATNM leads with a -85.6% price change compared with -100.0% for SDEV. Stablecoin Development is the larger company by market cap ($36.9 million vs $33.0 million), about 1.1 times the size.

On valuation, Stablecoin Development trades at a lower trailing P/E (0.2x vs 2.4x for Actinium Pharmaceuticals (Delaware)).

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ATNM-21.05%SDEV-88.37%
+2239%+1020%-199%
Nov 21, 20251 yearNov 20, 2026
ATNM-86.22%SDEV-99.98%
+79%-15%-109%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ATNM versus SDEV key metrics
MetricATNMSDEV
Share price$1.05$0.50
Market cap$33.01M$36.90M
1-day change-1.87%-10.30%
YTD return-22.79%-98.23%
1-year return-21.05%-88.37%
5-year return-85.60%-99.98%
P/E ratio (TTM)2.440.19
EPS (TTM)$0.43$2.70
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$90.00K—
Net income (latest FY)$-33.89M$-630.78M
Operating margin-40274.44%—
Net margin-37652.22%—
52-week high$1.72$99.75
52-week low$0.735$0.467
Distance from 52-week high-38.95%-99.50%
Analyst consensusnone—
Avg. price target upside+242.86%—
Average volume193.83K16.98M
Shares outstanding31.44M73.80M
Employees272
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ATNM has outperformed SDEV by 67.3 percentage points over the past year.
  • Actinium Pharmaceuticals (Delaware) trades at a higher earnings multiple (2.4x vs 0.2x trailing P/E).

About Actinium Pharmaceuticals (Delaware)

ATNM stock →

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies.

Health Care · Biotechnology: Pharmaceutical Preparations · 27 employees

About Stablecoin Development

SDEV stock →

Stablecoin Development Corporation engages in the accumulation and holding of digital assets for participation in blockchain-based networks. The company focuses on the accumulation, holding, and deployment of SKY, a protocol token of the decentralized Sky Protocol.

Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees

ATNM vs SDEV FAQ

Which is bigger, Actinium Pharmaceuticals (Delaware) or Stablecoin Development?

Stablecoin Development (SDEV) is larger, with a market capitalization of $36.90M compared with $33.01M for Actinium Pharmaceuticals (Delaware) (ATNM).

Which stock has performed better over the past year, ATNM or SDEV?

ATNM returned -21.05% over the past 12 months, compared with -88.37% for SDEV (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, ATNM or SDEV?

SDEV has the lower trailing P/E at 0.2, versus 2.4 for ATNM. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Are Actinium Pharmaceuticals (Delaware) and Stablecoin Development in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons